A Phase III Study of DPPE Combined With Epirubicin and Cyclophosphamide vs Epirubicin and Cyclophosphamide Alone as First Line Treatment in Metastatic/Recurrent Breast Cancer

Trial Profile

A Phase III Study of DPPE Combined With Epirubicin and Cyclophosphamide vs Epirubicin and Cyclophosphamide Alone as First Line Treatment in Metastatic/Recurrent Breast Cancer

Discontinued
Phase of Trial: Phase III

Latest Information Update: 02 Jun 2011

At a glance

  • Drugs Cyclophosphamide; Epirubicin; Tesmilifene
  • Indications Advanced breast cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors YM BioSciences
  • Most Recent Events

    • 26 Jul 2007 The expected completion date for this trial is now 1 Jun 2006.
    • 02 Feb 2007 Status changed from in progress to discontinued.
    • 19 Aug 2005 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top